{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:10:13Z","timestamp":1795029013208,"version":"4.10.2"},"reference-count":284,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["19430741500"],"award-info":[{"award-number":["19430741500"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007567","name":"City University of Hong Kong","doi-asserted-by":"publisher","award":["9610472"],"award-info":[{"award-number":["9610472"]}],"id":[{"id":"10.13039\/100007567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872823"],"award-info":[{"award-number":["81872823"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073782"],"award-info":[{"award-number":["82073782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.apsb.2020.12.018","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T15:49:53Z","timestamp":1609429793000},"page":"941-960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":214,"title":["Biological drug and drug delivery-mediated immunotherapy"],"prefix":"10.1016","volume":"11","author":[{"given":"Qingqing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-3831","authenticated-orcid":false,"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.12.018_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.addr.2019.12.001","article-title":"Drug delivery to macrophages: a review of targeting drugs and drug carriers to macrophages for inflammatory diseases","volume":"165-166","author":"He","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaci.2016.02.046","article-title":"Current concepts in chronic inflammatory diseases: interactions between microbes, cellular metabolism, and inflammation","volume":"138","author":"Garn","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaci.2004.03.024","article-title":"Mechanisms of immunotherapy","volume":"113","author":"Till","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib5","doi-asserted-by":"crossref","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2020.12.018_bib6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-0039-1683451","article-title":"Immunotherapy for atherosclerosis\u2014novel concepts","volume":"119","author":"Steffens","year":"2019","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.apsb.2020.12.018_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4110\/in.2016.16.1.44","article-title":"Dendritic cell-based immunotherapy for rheumatoid arthritis: from bench to bedside","volume":"16","author":"Ahmed","year":"2016","journal-title":"Immune Netw"},{"key":"10.1016\/j.apsb.2020.12.018_bib8","first-page":"2597","article-title":"Immunotherapy in inflammatory bowel disease: novel and emerging treatments","volume":"14","author":"Catalan-Serra","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.apsb.2020.12.018_bib9","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.201608-1630PP","article-title":"The roles of immunity in the prevention and evolution of pulmonary arterial hypertension","volume":"195","author":"Nicolls","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.12.018_bib11","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1530\/ERC-16-0404","article-title":"The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy","volume":"24","author":"Law","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.apsb.2020.12.018_bib12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.apsb.2020.12.018_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2020.12.018_bib14","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.apsb.2020.12.018_bib15","series-title":"Nivolumab (Opdivo)","author":"Hara","year":"2019"},{"key":"10.1016\/j.apsb.2020.12.018_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.currproblcancer.2018.08.010","article-title":"A newly approved checkpoint inhibitor for the treatment of urothelial carcinoma","volume":"43","author":"Wills","year":"2019","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.apsb.2020.12.018_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: a race to revolutionize cancer therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfus Med Hemotherapy"},{"key":"10.1016\/j.apsb.2020.12.018_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","article-title":"Current progress in innovative engineered antibodies","volume":"9","author":"Strohl","year":"2018","journal-title":"Protein cell"},{"key":"10.1016\/j.apsb.2020.12.018_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.apsb.2020.12.018_bib20","doi-asserted-by":"crossref","first-page":"a022236","DOI":"10.1101\/cshperspect.a022236","article-title":"Regulation of the immune response by TGF-\u03b2: from conception to autoimmunity and infection","volume":"9","author":"Sanjabi","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.apsb.2020.12.018_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd.2018.4","article-title":"2017 FDA drug approvals","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.12.018_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd3946","article-title":"2012 FDA drug approvals","volume":"12","author":"Mullard","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.12.018_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2020.12.018_bib24","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1053\/j.seminoncol.2015.10.001","article-title":"Practical approaches to immunotherapy in the clinic","volume":"42","author":"Agarwala","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.apsb.2020.12.018_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000479237","article-title":"A case of immune thrombocytopenia as a rare side effect of an immunotherapy with PD1-blocking agents for metastatic melanoma","volume":"44","author":"Pf\u00f6hler","year":"2017","journal-title":"Transfus Med Hemotherapy"},{"key":"10.1016\/j.apsb.2020.12.018_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0300-483X(95)03124-X","article-title":"Immune-mediated side-effects of cytokines in humans","volume":"105","author":"Vial","year":"1995","journal-title":"Toxicology"},{"key":"10.1016\/j.apsb.2020.12.018_bib27","doi-asserted-by":"crossref","first-page":"1910566","DOI":"10.1002\/adfm.201910566","article-title":"Nanocarrier-mediated cytosolic delivery of biopharmaceuticals","author":"He","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2019.08.003","article-title":"Unraveling the in\u00a0vivo fate and cellular pharmacokinetics of drug nanocarriers","volume":"143","author":"Wu","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2019.01.002","article-title":"Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers","volume":"143","author":"Zhao","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib30","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1016\/j.nano.2018.06.012","article-title":"A drug-delivering-drug strategy for combined treatment of metastatic breast cancer","volume":"14","author":"Xiao","year":"2018","journal-title":"Nanomed-Nanotechnol"},{"key":"10.1016\/j.apsb.2020.12.018_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.apsb.2017.12.002","article-title":"Biomimetic nanoparticles for inflammation targeting","volume":"8","author":"Jin","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.12.018_bib32","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cclet.2020.08.048","article-title":"Erythrocyte-derived drug\u00a0delivery systems in cancer therapy","volume":"32","author":"Mao","year":"2021","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2020.12.018_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","article-title":"Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine","volume":"143","author":"Donahue","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.addr.2019.06.008","article-title":"Absorption, distribution, metabolism and excretion of the biomaterials used in nanocarrier drug delivery systems","volume":"143","author":"Su","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib35","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.apsb.2020.08.010","article-title":"Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy","volume":"10","author":"Zhu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.12.018_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.apsb.2015.11.005","article-title":"Injected nanocrystals for targeted drug delivery","volume":"6","author":"Lu","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.12.018_bib37","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2020.12.018_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2020.12.018_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V68.2.493.493","article-title":"Treatment of hairy cell leukemia with recombinant alpha-interferon","volume":"68","author":"Quesada","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2020.12.018_bib40","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib42","doi-asserted-by":"crossref","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.apsb.2020.12.018_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2020.12.018_bib44","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2020.12.018_bib45","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","article-title":"Monoclonal antibodies in cancer immunotherapy","volume":"45","author":"Kimiz-Gebologlu","year":"2018","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.apsb.2020.12.018_bib46","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1007\/s00018-020-03459-1","article-title":"Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer","volume":"77","author":"Jafari","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2020.12.018_bib47","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2020.12.018_bib48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily-CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.12.018_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2015.08.021","article-title":"Rationale for anti-OX40 cancer immunotherapy","volume":"52","author":"Aspeslagh","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2020.12.018_bib50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.12.018_bib51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-2478(02)00088-3","article-title":"Microanatomical localization of PD-1 in human tonsils","volume":"83","author":"Iwai","year":"2002","journal-title":"Immunol Lett"},{"key":"10.1016\/j.apsb.2020.12.018_bib54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","article-title":"Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation","volume":"3","author":"Patsoukis","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2020.12.018_bib55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.apsb.2020.12.018_bib56","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2020.12.018_bib57","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.4110\/in.2020.20.e11","article-title":"Current status and future direction of immunotherapy in hepatocellular carcinoma: what do the data suggest?.","volume":"20","author":"Lee","year":"2020","journal-title":"Immune Netw"},{"key":"10.1016\/j.apsb.2020.12.018_bib58","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jtho.2017.03.010","article-title":"Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape","volume":"12","author":"Faruki","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.apsb.2020.12.018_bib59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00281-018-0703-z","article-title":"Principles of adoptive T cell therapy in cancer","volume":"41","author":"\u00d6","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.apsb.2020.12.018_bib60","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.12.018_bib61","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/annonc\/mdy139","article-title":"T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression","volume":"29","author":"Andersen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2020.12.018_bib62","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib64","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: a systematic review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.apsb.2020.12.018_bib65","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4049\/jimmunol.1500751","article-title":"Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street","volume":"195","author":"Barrett","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.apsb.2018.06.005","article-title":"Adapting liposomes for oral drug delivery","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.12.018_bib68","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.biomaterials.2016.01.006","article-title":"Combinatorial prospects of nano-targeted chemoimmunotherapy","volume":"83","author":"Da Silva","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.12.018_bib69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2019.07.009","article-title":"Optimizing advances in nanoparticle delivery for cancer immunotherapy","volume":"144","author":"Caster","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib70","first-page":"337","article-title":"PEGylation in anti-cancer therapy: an overview","volume":"11","author":"Mishra","year":"2016","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.apsb.2020.12.018_bib71","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41467-017-01830-8","article-title":"T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity","volume":"8","author":"Schmid","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.12.018_bib72","doi-asserted-by":"crossref","first-page":"9624532","DOI":"10.1155\/2020\/9624532","article-title":"Emerging prospects for nanoparticle-enabled cancer immunotherapy","volume":"2020","author":"Buabeid","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.addr.2019.09.005","article-title":"Physical and chemical profiles of nanoparticles for lymphatic targeting","volume":"151\u2013152","author":"Ke","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib74","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1002\/adma.201200446","article-title":"Engineering nano- and microparticles to tune immunity","volume":"24","author":"Moon","year":"2012","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.12.018_bib76","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.addr.2019.05.012","article-title":"Nuclear imaging of liposomal drug delivery systems: a critical review of radiolabelling methods and applications in nanomedicine","volume":"143","author":"Man","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2019.06.007","article-title":"Intratumoral fate of functional nanoparticles in response to microenvironment factor: implications on cancer diagnosis and therapy","volume":"143","author":"Peng","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib78","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2020.12.018_bib79","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1002\/adma.201506312","article-title":"Inflammation-triggered cancer immunotherapy by programmed delivery of CpG and anti-PD1 antibody","volume":"28","author":"Wang","year":"2016","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib80","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cclet.2017.01.021","article-title":"The in\u00a0vitro and in\u00a0vivo toxicity of gold nanoparticles","volume":"28","author":"Jia","year":"2017","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2020.12.018_bib81","doi-asserted-by":"crossref","first-page":"17571","DOI":"10.1039\/D0NR04156D","article-title":"Large scale assembly of nanomaterials: mechanisms and applications","volume":"12","author":"Yin","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2020.12.018_bib82","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1039\/C8CS00896E","article-title":"Recent advances in nanomaterial-based synergistic combination cancer immunotherapy","volume":"48","author":"Sang","year":"2019","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.02.004","article-title":"Checkpoint-based immunotherapy for autoimmune diseases \u2013 opportunities and challenges","volume":"79","author":"He","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.apsb.2020.12.018_bib84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nature17300","article-title":"Antigen-specific immunotherapy","volume":"530","author":"Wraith","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.12.018_bib85","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cei.12038","article-title":"Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?.","volume":"172","author":"Hilkens","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib86","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imr.12838","article-title":"Immunometabolism in the development of rheumatoid arthritis","volume":"294","author":"Weyand","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-017-1244-x","article-title":"Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis","volume":"19","author":"Salomon","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib88","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/imt-2019-0091","article-title":"Check-control of inflammation displayed by bone marrow mesenchymal stem cells in rheumatoid arthritis patients","volume":"11","author":"Lamas","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.apsb.2020.12.018_bib89","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF\u03b1 therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib90","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.intimp.2019.03.064","article-title":"New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases","volume":"72","author":"Xu","year":"2019","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.apsb.2020.12.018_bib91","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.molmed.2016.01.005","article-title":"Novel immunotherapeutic avenues for rheumatoid arthritis","volume":"22","author":"Semerano","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib92","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molimm.2014.01.014","article-title":"Cellular targets of regulatory B cell-mediated suppression","volume":"62","author":"Rosser","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib93","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2016.07.006","article-title":"Role of regulatory B cells in immune tolerance to allergens and beyond","volume":"138","author":"Veen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00961","article-title":"IL-10 producing B cells ability to induce regulatory T cells is maintained in rheumatoid arthritis","volume":"9","author":"Mielle","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib95","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/art.38666","article-title":"Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity","volume":"66","author":"Daien","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.apsb.2020.12.018_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005407","article-title":"CD19+ CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib97","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1084\/jem.20021293","article-title":"Prevention of arthritis by interleukin 10\u2013producing B cells","volume":"197","author":"Mauri","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib98","first-page":"525","article-title":"Antigen-specific immunotherapies in rheumatic diseases","volume":"13","author":"Pozsgay","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib99","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/hum.2018.042","article-title":"Vaccination with a novel antigen-specific tolerizing DNA vaccine encoding CCOL2A1 protects rats from experimental rheumatoid arthritis","volume":"30","author":"Zhao","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib100","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S243636","article-title":"Role of chemokines and chemokine receptors in rheumatoid arthritis","volume":"9","author":"Elemam","year":"2020","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","article-title":"Cytokines in rheumatoid arthritis-shaping the immunological landscape","volume":"12","author":"McInnes","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.apsb.2020.12.018_bib103","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13075-018-1725-6","article-title":"Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review","volume":"20","author":"Davignon","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib104","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.4049\/jimmunol.165.10.5621","article-title":"TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3\u2212CD4\u2212CD8\u2212) subset","volume":"165","author":"Baseta","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cellimm.2012.09.001","article-title":"Anti-TNF-\u03b1 therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis","volume":"279","author":"Huang","year":"2012","journal-title":"Cell Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib106","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.12.018_bib107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2017.05.012","article-title":"Regulatory B cells in rheumatoid arthritis: alterations in patients receiving anti-TNF therapy","volume":"184","author":"Bank\u00f3","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib108","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/1744666X.2017.1295850","article-title":"The role and therapeutic targeting of IL-6 in rheumatoid arthritis","volume":"13","author":"Narazaki","year":"2017","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib109","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-020-2097-2","article-title":"Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug","volume":"22","author":"Samarpita","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/rheumatology\/key338","article-title":"Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry","volume":"58","author":"Olsen","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.apsb.2020.12.018_bib111","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cbpa.2016.03.006","article-title":"Janus kinase inhibitors for rheumatoid arthritis","volume":"32","author":"Yamaoka","year":"2016","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.apsb.2020.12.018_bib112","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.apsb.2020.12.018_bib113","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1080\/14656566.2016.1241237","article-title":"Chemical JAK inhibitors for the treatment of rheumatoid arthritis","volume":"17","author":"Nakayamada","year":"2016","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.apsb.2020.12.018_bib114","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2217\/nnm-2016-0410","article-title":"Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis","volume":"12","author":"Pujol-Autonell","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2020.12.018_bib115","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ymthe.2019.05.002","article-title":"Lipidoid-siRNA nanoparticle-mediated IL-1\u03b2 gene silencing for systemic arthritis therapy in a mouse model","volume":"27","author":"Song","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib116","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.4049\/jimmunol.0802972","article-title":"Antigen-specific suppression of inflammatory arthritis using liposomes","volume":"182","author":"Capini","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib117","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2020.12.018_bib118","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/nnm-2019-0385","article-title":"Development of novel pH-sensitive nanoparticle-based transdermal patch for management of rheumatoid arthritis","volume":"15","author":"Khan","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2020.12.018_bib119","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2016.08.020","article-title":"Folate receptor targeted three-layered micelles and hydrogels for gene delivery to activated macrophages","volume":"244","author":"Mohammadi","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib120","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1021\/nn500685h","article-title":"Hyaluronate\u2013gold nanoparticle\/tocilizumab complex for the treatment of rheumatoid arthritis","volume":"8","author":"Lee","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2020.12.018_bib121","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/nnm-2019-0388","article-title":"Cell membrane-coated nanoparticles: research advances","volume":"15","author":"Zou","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2020.12.018_bib122","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1007\/s12274-018-2126-5","article-title":"Drug targeting through platelet membrane-coated nanoparticles for the treatment of rheumatoid arthritis","volume":"11","author":"He","year":"2018","journal-title":"Nano Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib123","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41565-018-0254-4","article-title":"Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis","volume":"13","author":"Zhang","year":"2018","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2020.12.018_bib124","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4155\/tde-2020-0029","article-title":"Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status","volume":"11","author":"Gorantla","year":"2020","journal-title":"Ther Deliv"},{"key":"10.1016\/j.apsb.2020.12.018_bib125","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.nano.2015.12.365","article-title":"Folate-targeted nanoparticles for rheumatoid arthritis therapy","volume":"12","author":"Nogueira","year":"2016","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib126","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-019-0054-9","article-title":"Potent delivery of an MMP inhibitor to the tumor microenvironment with thermosensitive liposomes for the suppression of metastasis and angiogenesis","volume":"4","author":"Lyu","year":"2019","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.apsb.2020.12.018_bib127","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12951-018-0382-x","article-title":"Combination of NF-\u03baB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis","volume":"16","author":"Duan","year":"2018","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2020.12.018_bib128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41586-020-2025-2","article-title":"Pathway paradigms revealed from the genetics of inflammatory bowel disease","volume":"578","author":"Graham","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.12.018_bib129","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/mi.2015.49","article-title":"Regulatory immune cells in regulation of intestinal inflammatory response to microbiota","volume":"8","author":"Sun","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib130","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10208","article-title":"Intestinal homeostasis and its breakdown in inflammatory bowel disease","volume":"474","author":"Maloy","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.12.018_bib131","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2012-303955","article-title":"Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation","volume":"62","author":"Cader","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.apsb.2020.12.018_bib132","doi-asserted-by":"crossref","first-page":"S641","DOI":"10.1093\/ecco-jcc\/jjx145","article-title":"Chemokines and chemokine receptors as therapeutic targets in inflammatory bowel disease; pitfalls and promise","volume":"12","author":"Trivedi","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.apsb.2020.12.018_bib133","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000445986","article-title":"New and evolving immunotherapy in inflammatory bowel disease","volume":"1","author":"Raad","year":"2016","journal-title":"Inflammatory Intestinal Diseases"},{"key":"10.1016\/j.apsb.2020.12.018_bib134","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2020.12.018_bib135","first-page":"157","article-title":"Chapter Five - inflammatory bowel disease and targeted oral anti-TNF\u03b1 therapy","volume":"119","author":"Griffiths","year":"2020","journal-title":"Adv Protein Chem Str"},{"key":"10.1016\/j.apsb.2020.12.018_bib136","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.nantod.2017.08.006","article-title":"Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease","volume":"16","author":"Zhang","year":"2017","journal-title":"Nano Today"},{"key":"10.1016\/j.apsb.2020.12.018_bib137","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2013.10.001","article-title":"Drug delivery strategies in the therapy of inflammatory bowel disease","volume":"71","author":"Lautenschl\u00e4ger","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib138","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2019.01.023","article-title":"Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals","volume":"296","author":"Vass","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib139","doi-asserted-by":"crossref","first-page":"110486","DOI":"10.1016\/j.biopha.2020.110486","article-title":"Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease","volume":"129","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2020.12.018_bib140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.addr.2004.08.011","article-title":"New oral delivery systems for treatment of inflammatory bowel disease","volume":"57","author":"Friend","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib141","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejpb.2020.08.017","article-title":"Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease","volume":"155","author":"Zhang","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2020.12.018_bib142","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2017.07.044","article-title":"Self-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitis","volume":"275","author":"Courthion","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib143","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2018.08.021","article-title":"TNF\u03b1 gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis","volume":"287","author":"Xiao","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib144","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jconrel.2020.10.042","article-title":"Improving silymarin oral bioavailability using silica-installed redox nanoparticle to suppress inflammatory bowel disease","volume":"331","author":"Nguyen","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib145","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","article-title":"Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue","volume":"11","author":"Hua","year":"2015","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib146","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.11.003","article-title":"Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model","volume":"138","author":"Laroui","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2020.12.018_bib147","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/acs.biomac.5b01518","article-title":"Enzyme- and pH-responsive microencapsulated manogels for oral delivery of siRNA to induce TNF-alpha knockdown in the intestine","volume":"17","author":"Knipe","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.apsb.2020.12.018_bib148","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ymthe.2016.11.020","article-title":"Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis","volume":"25","author":"Xiao","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib149","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5657","article-title":"An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease","volume":"7","author":"Zhang","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2015.05.275","article-title":"Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose\u2013response efficacy","volume":"210","author":"Vong","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib151","doi-asserted-by":"crossref","first-page":"1900610","DOI":"10.1002\/advs.201900610","article-title":"A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota","volume":"6","author":"Li","year":"2019","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2020.12.018_bib152","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jconrel.2019.10.054","article-title":"A self-assembled, ROS-responsive janus-prodrug for targeted therapy of inflammatory bowel disease","volume":"316","author":"Li","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib153","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.nano.2018.01.003","article-title":"pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions","volume":"14","author":"Naeem","year":"2018","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib154","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1016\/j.biomaterials.2013.06.008","article-title":"Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-\u03b1 RNA interference for IBD therapy","volume":"34","author":"Xiao","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.12.018_bib155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2018.12.074","article-title":"Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease","volume":"558","author":"Zeeshan","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2020.12.018_bib156","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41563-019-0462-9","article-title":"Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis","volume":"19","author":"Lee","year":"2020","journal-title":"Nat Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib157","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.carbpol.2016.01.026","article-title":"Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa","volume":"144","author":"Vafaei","year":"2016","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2020.12.018_bib158","doi-asserted-by":"crossref","first-page":"1901805","DOI":"10.1002\/adhm.201901805","article-title":"A novel strategy for treating inflammatory bowel disease by targeting delivery of methotrexate through glucan particles","volume":"9","author":"Sun","year":"2020","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib159","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/ecco-jcc\/jjx115","article-title":"Oral delivery of nanoparticles loaded with ginger active compound, 6-shogaol, attenuates ulcerative colitis and promotes wound healing in a murine model of ulcerative colitis","volume":"12","author":"Zhang","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.apsb.2020.12.018_bib160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijpharm.2014.07.009","article-title":"pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease","volume":"473","author":"Beloqui","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2020.12.018_bib161","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.3390\/nu11092216","article-title":"Beneficial effects of dietary polyphenols on gut microbiota and strategies to improve delivery efficiency","volume":"11","author":"Singh","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.apsb.2020.12.018_bib162","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/acs.chemmater.8b01173","article-title":"Rational design of polyphenol-poloxamer nanovesicles for targeting inflammatory bowel disease therapy","volume":"30","author":"Wang","year":"2018","journal-title":"Chem Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib163","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2018.08.004","article-title":"Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): formulation development, characterization and pharmacological evaluation","volume":"290","author":"Kesharwani","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib164","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biomaterials.2015.01.013","article-title":"An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease","volume":"48","author":"Huang","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2020.12.018_bib165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2019.04.011","article-title":"Thermoreversible mucoadhesive polymer-drug dispersion for sustained local delivery of budesonide to treat inflammatory disorders of the GI tract","volume":"303","author":"Antonino","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib166","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addr.2020.07.010","article-title":"Advanced nanomedicines for the treatment of inflammatory diseases","volume":"157","author":"Brusini","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib167","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.apsb.2020.06.005","article-title":"Intracellular codelivery of anti-inflammatory drug and anti-miR 155 to treat inflammatory disease","volume":"10","author":"Teng","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.12.018_bib168","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.apsb.2020.07.019","article-title":"Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.12.018_bib169","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/cr.2011.196","article-title":"Immunosuppressive exosomes from TGF-\u03b21 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells","volume":"22","author":"Cai","year":"2012","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib170","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1126\/science.1990440","article-title":"Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis","volume":"251","author":"Cybulsky","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.apsb.2020.12.018_bib171","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrneph.2017.51","article-title":"The immunology of atherosclerosis","volume":"13","author":"Gister\u00e5","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.apsb.2020.12.018_bib172","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1160\/TH11-08-0592","article-title":"Platelets in atherosclerosis","volume":"106","author":"Lievens","year":"2011","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.apsb.2020.12.018_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15781","article-title":"Type-2 innate lymphoid cells control the development of atherosclerosis in mice","volume":"8","author":"Newland","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.12.018_bib174","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Bor\u00e9n","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.apsb.2020.12.018_bib175","first-page":"136","article-title":"CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima","volume":"119","author":"Park","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2020.12.018_bib176","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.2205","article-title":"The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques","volume":"13","author":"Van Gils","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib177","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nri3520","article-title":"Macrophages in atherosclerosis: a dynamic balance","volume":"13","author":"Moore","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib178","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI63108","article-title":"Adaptive immunity in atherogenesis: new insights and therapeutic approaches","volume":"123","author":"Lichtman","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2020.12.018_bib179","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib180","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.acvd.2016.04.002","article-title":"Inflammation in atherosclerosis","volume":"109","author":"Taleb","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.apsb.2020.12.018_bib181","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/eurheartj\/ehv759","article-title":"Inflammatory cytokines in atherosclerosis: current therapeutic approaches","volume":"37","author":"Tousoulis","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2020.12.018_bib182","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/eurheartj\/ehw248","article-title":"Novel mechanisms of atherosclerosis and cardiovascular repair","volume":"37","author":"L\u00fcscher","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2020.12.018_bib183","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib184","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2020.12.018_bib185","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2020.12.018_bib186","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1161\/ATVBAHA.118.307742","article-title":"2016 Jeffrey M. Hoeg award lecture: immune checkpoints in atherosclerosis: toward immunotherapy for atheroprotection","volume":"38","author":"Rouwet","year":"2018","journal-title":"Atertio Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2020.12.018_bib187","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/DDDT.S59594","article-title":"Inhibition of B7-1 (CD80) by RhuDex\u00ae reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions","volume":"8","author":"Doesch","year":"2014","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-015-0157-4","article-title":"Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis","volume":"6","author":"Meletta","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib189","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijcard.2014.04.071","article-title":"Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules","volume":"174","author":"M\u00fcller","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.apsb.2020.12.018_bib190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20091293","article-title":"Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile","volume":"207","author":"Lutgens","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib191","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1073\/pnas.97.13.7458","article-title":"Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice","volume":"97","author":"Sch\u00f6nbeck","year":"2000","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.apsb.2020.12.018_bib192","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","article-title":"Reduction of atherosclerosis in mice by inhibition of CD40 signalling","volume":"394","author":"Mach","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.12.018_bib193","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/15271","article-title":"Requirement for CD154 in the progression of atherosclerosis","volume":"5","author":"Lutgens","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib194","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/ATVBAHA.113.301655","article-title":"Chemokines in atherosclerosis: proceedings resumed","volume":"34","author":"Zernecke","year":"2014","journal-title":"Arterioscl Throm Vas"},{"key":"10.1016\/j.apsb.2020.12.018_bib195","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00109-015-1317-8","article-title":"Chemokines and their receptors in atherosclerosis","volume":"93","author":"EPCvd","year":"2015","journal-title":"J Mol Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib196","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/ATVBAHA.118.312037","article-title":"Chemokines as therapeutic targets in cardiovascular disease","volume":"39","author":"Noels","year":"2019","journal-title":"Arterioscl Throm Vas"},{"key":"10.1016\/j.apsb.2020.12.018_bib197","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1476-5381.2010.01147.x","article-title":"Chemokine receptor CCR5: from AIDS to atherosclerosis","volume":"162","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2020.12.018_bib198","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1160\/TH11-07-0453","article-title":"The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation","volume":"107","author":"Hamesch","year":"2012","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.apsb.2020.12.018_bib199","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1538-7836.2008.03086.x","article-title":"A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury","volume":"6","author":"Karshovska","year":"2008","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.apsb.2020.12.018_bib200","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1093\/eurheartj\/ehz283","article-title":"Immunotherapy for cardiovascular disease","volume":"40","author":"Lutgens","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2020.12.018_bib201","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1084\/jem.20150900","article-title":"The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease","volume":"213","author":"Shirai","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.celrep.2015.05.046","article-title":"mTORC1-induced HK1-dependent glycolysis regulates NLRP3 inflammasome activation","volume":"12","author":"Moon","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2020.12.018_bib203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cmet.2006.05.011","article-title":"Oxidative metabolism and PGC-1\u03b2 attenuate macrophage-mediated inflammation","volume":"4","author":"Vats","year":"2006","journal-title":"Cell Metabol"},{"key":"10.1016\/j.apsb.2020.12.018_bib204","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","article-title":"Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets","volume":"186","author":"Michalek","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib205","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.immuni.2011.12.007","article-title":"Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development","volume":"36","author":"GJvd","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2020.12.018_bib206","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2016.11.018","article-title":"Hematopoietic arginase 1 deficiency results in decreased leukocytosis and increased foam cell formation but does not affect atherosclerosis","volume":"256","author":"Ren","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2020.12.018_bib207","doi-asserted-by":"crossref","first-page":"13033","DOI":"10.1073\/pnas.1517820112","article-title":"Indoleamine 2, 3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development","volume":"112","author":"Cole","year":"2015","journal-title":"P Natl Acad Sci Usa"},{"key":"10.1016\/j.apsb.2020.12.018_bib208","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1194\/jlr.CX00001-JLR200","article-title":"Errata. PCSK9 function and physiology","volume":"49","author":"Peterson","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib209","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1194\/jlr.R400007-JLR200","article-title":"A review of CETP and its relation to atherosclerosis","volume":"45","author":"Grooth","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib210","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apsb.2020.12.018_bib211","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2020.12.018_bib212","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in\u00a0vivo and reduce aortic lesions in a rabbit model of atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Arterioscl Throm Vas"},{"key":"10.1016\/j.apsb.2020.12.018_bib213","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib214","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.atherosclerosis.2009.08.041","article-title":"Vaccination against Foxp3+ regulatory T cells aggravates atherosclerosis","volume":"209","author":"Tv","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2020.12.018_bib215","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/aps.2017.140","article-title":"Regulatory T cells as a new therapeutic target for atherosclerosis","volume":"39","author":"Ou","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2020.12.018_bib216","doi-asserted-by":"crossref","first-page":"13759","DOI":"10.1021\/acsnano.8b08875","article-title":"Nanoparticle-aided characterization of arterial endothelial architecture during atherosclerosis progression and metabolic therapy","volume":"13","author":"Beldman","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2020.12.018_bib217","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12916-019-1457-8","article-title":"Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis","volume":"17","author":"Momtazi-Borojeni","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib218","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drudis.2019.09.005","article-title":"A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome","volume":"25","author":"Kiaie","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2020.12.018_bib219","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.11.055","article-title":"Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis","volume":"71","author":"Seijkens","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apsb.2020.12.018_bib220","doi-asserted-by":"crossref","first-page":"1801545","DOI":"10.1002\/adhm.201801545","article-title":"Atheroma niche-responsive nanocarriers for immunotherapeutic delivery","volume":"8","author":"Peters","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib221","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nano.2018.08.002","article-title":"Platelet membrane-coated nanoparticle-mediated targeting delivery of rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE\u2212\/\u2212) mice","volume":"15","author":"Song","year":"2019","journal-title":"Nanomed-Nanotechnol"},{"key":"10.1016\/j.apsb.2020.12.018_bib222","doi-asserted-by":"crossref","first-page":"11290","DOI":"10.1021\/acsnano.6b06451","article-title":"Tailoring nanostructure morphology for enhanced targeting of dendritic cells in atherosclerosis","volume":"10","author":"Yi","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2020.12.018_bib223","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/hh2401.101272","article-title":"CD40 signaling and plaque instability","volume":"89","author":"Sch\u00f6nbeck","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib224","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41551-018-0221-2","article-title":"Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates","volume":"2","author":"Lameijer","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2020.12.018_bib225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1736-5","article-title":"The P-selectin and PSGL-1 axis accelerates atherosclerosis via activation of dendritic cells by the TLR4 signaling pathway","volume":"10","author":"Ye","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2020.12.018_bib226","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1172\/JCI64617","article-title":"Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs","volume":"123","author":"Subramanian","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2020.12.018_bib227","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/ATVBAHA.114.303568","article-title":"Treating atherosclerosis with regulatory T cells","volume":"35","author":"Foks","year":"2015","journal-title":"Atertio Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2020.12.018_bib228","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/CIRCRESAHA.109.210781","article-title":"Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis","volume":"106","author":"Paulson","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib229","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1172\/JCI44925","article-title":"CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice","volume":"121","author":"Weber","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2020.12.018_bib230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clim.2009.05.006","article-title":"Dendritic cells in atherosclerotic disease","volume":"134","author":"Niessner","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib231","doi-asserted-by":"crossref","first-page":"1904399","DOI":"10.1002\/adfm.201904399","article-title":"Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapy","volume":"29","author":"Yi","year":"2019","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib232","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2018.10.028","article-title":"Anionic 1, 2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG) liposomes induce antigen-specific regulatory T cells and prevent atherosclerosis in mice","volume":"291","author":"Benne","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2020.12.018_bib233","doi-asserted-by":"crossref","first-page":"2002131","DOI":"10.1002\/adfm.202002131","article-title":"Site-specific microRNA-33 antagonism by pH-responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity","author":"Li","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2020.12.018_bib234","doi-asserted-by":"crossref","first-page":"64","DOI":"10.21037\/jtd.2017.12.47","article-title":"The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1\u03b2 and vascular inflammation","volume":"10","author":"Berm\u00fadez","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.apsb.2020.12.018_bib235","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1039\/D0BM00418A","article-title":"Biomimetic oral targeted delivery of bindarit for immunotherapy of atherosclerosis","volume":"8","author":"Yin","year":"2020","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2020.12.018_bib236","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/1755-5922.12201","article-title":"Oral administration of recombinant mycobacterium smegmatis expressing a tripeptide construct derived from endogenous and microbial antigens prevents atherosclerosis in ApoE\u2212\/\u2212 mice","volume":"34","author":"Deshpande","year":"2016","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib237","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10557-019-06890-0","article-title":"Long-term efficacy and safety of immunomodulatory therapy for atherosclerosis","volume":"33","author":"Thota","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.apsb.2020.12.018_bib238","doi-asserted-by":"crossref","first-page":"100529","DOI":"10.1016\/j.ijcha.2020.100529","article-title":"Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis","volume":"28","author":"Sato-Okabayashi","year":"2020","journal-title":"IJC Heart & Vasculature"},{"key":"10.1016\/j.apsb.2020.12.018_bib239","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00299-016-1946-6","article-title":"Chlamydomonas reinhardtii chloroplasts express an orally immunogenic protein targeting the p210 epitope implicated in atherosclerosis immunotherapies","volume":"35","author":"Beltr\u00e1n-L\u00f3pez","year":"2016","journal-title":"Plant Cell Rep"},{"key":"10.1016\/j.apsb.2020.12.018_bib240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jbiotec.2019.12.007","article-title":"Using carrot cells as biofactories and oral delivery vehicles of LTB-Syn: a low-cost vaccine candidate against synucleinopathies","volume":"309","author":"Arevalo-Villalobos","year":"2020","journal-title":"J Biotechnol"},{"key":"10.1016\/j.apsb.2020.12.018_bib241","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2020.12.018_bib242","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/abbs\/gmx095","article-title":"Immune cells and autoantibodies in pulmonary arterial hypertension","volume":"49","author":"Li","year":"2017","journal-title":"Acta Biochim Biophys Sin"},{"key":"10.1016\/j.apsb.2020.12.018_bib243","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.3892\/mmr.2014.3106","article-title":"Regulatory T cells protect against hypoxia-induced pulmonary arterial hypertension in mice","volume":"11","author":"Chu","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2020.12.018_bib244","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.yexcr.2017.06.017","article-title":"An upregulation of CD8+ CD25+ Foxp3+ T cells with suppressive function through interleukin 2 pathway in pulmonary arterial hypertension","volume":"358","author":"Zhu","year":"2017","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib245","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014201","article-title":"The role of regulatory T Cells in pulmonary arterial hypertension","volume":"8","author":"Qiu","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.apsb.2020.12.018_bib246","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature23665","article-title":"Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling","volume":"548","author":"Yang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.12.018_bib247","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1073\/pnas.1620835114","article-title":"IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors","volume":"114","author":"Whitehouse","year":"2017","journal-title":"P Natl Acad Sci Usa"},{"key":"10.1016\/j.apsb.2020.12.018_bib248","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/HYPERTENSIONAHA.116.07084","article-title":"Increasing regulatory T cells with interleukin-2 and interleukin-2 antibody complexes attenuates lung inflammation and heart failure progression","volume":"68","author":"Wang","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2020.12.018_bib249","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12026-016-8829-3","article-title":"Vitamin D supplementation effects on FoxP3 expression in T cells and FoxP3+\/IL-17A ratio and clinical course in systemic lupus erythematosus patients: a study in a Portuguese cohort","volume":"65","author":"Marinho","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib250","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/eji.201343967","article-title":"Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412\/TAB08","volume":"44","author":"Tabares","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib251","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.12.018_bib252","doi-asserted-by":"crossref","first-page":"315ra18","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib253","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall'Era","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.apsb.2020.12.018_bib254","first-page":"RCT1884","article-title":"Late Breaking Abstract-Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension","volume":"54","author":"Zamanian","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2020.12.018_bib255","article-title":"A checkpoint on innate myeloid cells in pulmonary arterial hypertension","volume":"9","author":"Bryant","year":"2018","journal-title":"Pulm Circ"},{"key":"10.1016\/j.apsb.2020.12.018_bib256","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.201608-1630PP","article-title":"The roles of immunity in the prevention and evolution of pulmonary arterial hypertension. A perspective","volume":"195","author":"Nicolls","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib257","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib258","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/jmv.24138","article-title":"Induction of interleukin-1 beta (IL-1\u03b2) is a critical component of lung inflammation during influenza A (H1N1) virus infection","volume":"87","author":"Kim","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.apsb.2020.12.018_bib259","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1465-9921-15-47","article-title":"Inflammatory cytokines in pulmonary hypertension","volume":"15","author":"Groth","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib260","article-title":"Clinical trial protocol for TRANSFORM-UK: a therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension","volume":"8","author":"Hern\u00e1ndez-S\u00e1nchez","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib261","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.vph.2012.07.006","article-title":"Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-\u03b1 antagonists via the suppression of TNF-\u03b1 expression and NF-\u03baB pathway in rats","volume":"58","author":"Wang","year":"2013","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.apsb.2020.12.018_bib262","series-title":"Inflammatory cytokines in the pathogenesis of pulmonary arterial hypertension","author":"Nakaoka","year":"2020"},{"key":"10.1016\/j.apsb.2020.12.018_bib263","first-page":"1","article-title":"The role of chemokines and chemokine receptors in pulmonary arterial hypertension","volume":"195","author":"Mamazhakypov","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2020.12.018_bib264","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006674","article-title":"Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension","volume":"5","author":"Tian","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib265","doi-asserted-by":"crossref","first-page":"172823","DOI":"10.1016\/j.ejphar.2019.172823","article-title":"Leukotriene B4 induces proliferation of rat pulmonary arterial smooth muscle cells via modulating GSK-3\u03b2\/\u03b2-catenin pathway","volume":"867","author":"Li","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2020.12.018_bib266","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","article-title":"The endothelin system in pulmonary arterial hypertension","volume":"61","author":"Gali\u00e9","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.apsb.2020.12.018_bib267","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.jacc.2019.02.067","article-title":"Immunotherapy of endothelin-1 receptor type a for pulmonary arterial hypertension","volume":"73","author":"Dai","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apsb.2020.12.018_bib268","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/HYPERTENSIONAHA.119.13700","article-title":"Vaccine targeted alpha 1D-adrenergic receptor for hypertension","volume":"74","author":"Li","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2020.12.018_bib269","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1124\/jpet.118.247643","article-title":"Cerivastatin nanoliposome as a potential disease modifying approach for the treatment of pulmonary arterial hypertension","volume":"366","author":"Lee","year":"2018","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2020.12.018_bib270","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s13346-019-00641-2","article-title":"Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach","volume":"9","author":"Dhoble","year":"2019","journal-title":"Drug Deliv Transl Re"},{"key":"10.1016\/j.apsb.2020.12.018_bib271","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.108.121418","article-title":"Nanoparticle-mediated delivery of nuclear factor B decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension","volume":"53","author":"Kimura","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2020.12.018_bib272","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/HYPERTENSIONAHA.110.157032","article-title":"Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension","volume":"57","author":"Chen","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2020.12.018_bib273","first-page":"427","article-title":"Poly(lactic acid)\/poly (lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery","volume":"49","author":"Emami","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2020.12.018_bib274","first-page":"481","article-title":"Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges","volume":"10","author":"Lee","year":"2015","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.apsb.2020.12.018_bib275","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib276","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2020.12.018_bib277","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.201411-2061LE","article-title":"Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension","volume":"192","author":"Spiekerkoetter","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2020.12.018_bib278","doi-asserted-by":"crossref","first-page":"1602449","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2020.12.018_bib279","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijpharm.2016.08.047","article-title":"Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension","volume":"512","author":"Wang","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2020.12.018_bib280","doi-asserted-by":"crossref","first-page":"110355","DOI":"10.1016\/j.biopha.2020.110355","article-title":"Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: an update","volume":"129","author":"Yang","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2020.12.018_bib281","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2020.12.018_bib282","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.canlet.2019.07.017","article-title":"Adoptive CD8+ T cell therapy against cancer: challenges and opportunities","volume":"462","author":"Jiang","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2020.12.018_bib283","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2019.05.009","article-title":"Towards more accurate bioimaging of drug nanocarriers: turning aggregation-caused quenching into a useful tool","volume":"143","author":"Qi","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2020.12.018_bib284","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2018.183","article-title":"Non-invasive delivery strategies for biologics","volume":"18","author":"Anselmo","year":"2019","journal-title":"Nat Rev Drug Discov"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520308674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520308674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:48:16Z","timestamp":1761929296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383520308674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":284,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2211383520308674"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.12.018","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological drug and drug delivery-mediated immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}